Huntington'S Disease Genetic Variants represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by CAG trinucleotide repeat expansions in the HTT gene. Unlike most neurodegenerative diseases, HD has a single deterministic genetic cause, making it a unique model for understanding disease mechanisms and developing therapies. This page provides a comprehensive overview of HD genetic variants, their molecular mechanisms, and therapeutic implications.
Huntington's disease affects approximately 30,000 Americans, with an additional 150,000 at risk of developing the disease. It is characterized by:
The disease typically begins in middle age (35-50 years) and progresses over 15-20 years to death.
The HTT gene (also called IT15 - "interesting transcript 15") is located on chromosome 4p16.3 and encodes huntingtin, a large protein of 3,144 amino acids. Huntingtin is essential for normal development and is expressed ubiquitously in the brain and peripheral tissues.
Wild-type huntingtin plays important roles in:
HD is caused by an unstable CAG trinucleotide repeat expansion in the first exon of the HTT gene. The normal repeat length is:
| CAG Repeats | Disease Status | Age of Onset |
|---|---|---|
| < 27 | Normal | N/A |
| 27-35 | Intermediate | N/A (possible anticipation in offspring) |
| 36-39 | Reduced penetrance | Variable, often later |
| 40-50 | Full penetrance | ~60 years |
| 51-90 | Full penetrance | ~40 years |
| > 90 | Full penetrance | ~20 years (juvenile HD) |
The disease shows anticipation, meaning it presents earlier in successive generations. This is due to:
When onset occurs before age 20, the disease is termed "juvenile HD" (Westphal variant). Features include:
While HTT is the causative gene, several modifier genes influence age of onset and disease progression:
The CAG repeat length accounts for ~50-70% of variation in age of onset.
Variants in DNA repair genes can modify onset:
Genetic testing for HD is available for:
The Huntington's Disease Society of America recommends:
Several approaches are being developed to lower mutant huntingtin:
While disease-modifying treatments are in development, current treatments focus on symptom management:
The study of Huntington'S Disease Genetic Variants has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.